Kathleen Rodgers

Dr. Rodgers’ research over the last 30 years has evaluated the ability of angiotensin peptides and small molecule Mas agonists to mitigate injury and regenerate injured tissues and product development. Stimulation of Mas through endogenous peptides, analogues and peptidomimetics has been shown to increase stem cells/progenitors in a number of disease states with a deficit regenerative cells and to reduce oxidative stress and inflammation. By targeting these three fundamental processes, a platform leading to clinical development from laboratory observations has led has been generated. Current disease targets include vascular dementia, Alzheimer’s Disease and multiple sclerosis. Dr. Rodgers has deep domain knowledge in therapeutic development that spans discovery, IND-enabling pharmacology and toxicology, clinical trial design and regulatory submissions. She has designed and conducted numerous clinical trials and holds over 50 US patents with expanded coverage in major therapeutic indications.